United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - adrenalin® is available as a single-use 1 ml vial and a multiple-use 30 ml vial for intramuscular and subcutaneous use. emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. none. 8.1 pregnancy teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies in pregnant women. epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (fetal

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with iv or im dosing of ketorolac tromethamine and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and adverse reactions). patients

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate injection, usp is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis — e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. but since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total co 2 content is crucial — e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. specific concentrations and presentations of bupivacaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see dosage and administration]. limitations of use not all blocks are indicated for use with bupivacaine hydrochloride injection given clinically significant risks associated with use [see dosage and administration, contraindications, warnings and precautions]. bupivacaine hydrochloride is contraindicated in: obstetrical paracervical block anesthesia. its use in this technique has resulted in fetal bradycardia and death. intravenous regional anesthesia (bier block) [see warnings and precautions]. patients with a known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of bupivacaine hydrochloride injection. 8.1 pregnancy risk summary bupivacaine hydrochloride is contraindicated for obstetrical paracervical block anesthesia. its use in this technique has resulted in fetal bradycardia and death [see contraindications, warnings and precautions]. there are no available data on use of bupivacaine hydrochloride in pregnant women to inform a drug-associated risk of adverse developmental outcomes. in animal studies, embryo-fetal lethality was noted when bupivacaine was administered subcutaneously to pregnant rabbits during organogenesis at clinically relevant doses. decreased pup survival was observed in a rat pre-and post-natal developmental study (dosing from implantation through weaning) at a dose level comparable to the daily maximum recommended human dose (mrhd) on a body surface area (bsa) basis. based on animal data, advise pregnant women of the potential risks to a fetus (see data). local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity [see clinical pharmacology]. the incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. adverse reactions in the parturient, fetus, and neonate involve alterations of the cns, peripheral vascular tone, and cardiac function. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, inform the patient of the potential hazard to the fetus. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations maternal adverse reactions maternal hypotension has resulted from regional anesthesia. local anesthetics produce vasodilation by blocking sympathetic nerves. the supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. therefore, during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible, or manual displacement of the uterus off the great vessels be accomplished. elevating the patient's legs will also help prevent decreases in blood pressure. the fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable. labor or delivery epidural, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient's reflex urge to bear down or by interfering with motor function. the use of obstetrical anesthesia may increase the need for forceps assistance. the use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. this has not been reported with bupivacaine. it is extremely important to avoid aortocaval compression by the gravid uterus during administration of regional block to parturients. to do this, the patient must be maintained in the left lateral decubitus position or a blanket roll or sandbag may be placed beneath the right hip and gravid uterus displaced to the left. data animal data bupivacaine hydrochloride produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses. bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, & 40 mg/kg and to rabbits at doses of 1.3, 5.8, & 22.2 mg/kg during the period of organogenesis (implantation to closure of the hard palate). the high doses are comparable to the daily mrhd of 400 mg/day on a mg/m2 bsa basis. no embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality. an increase in embryo-fetal deaths was observed in rabbits at the high dose in the absence of maternal toxicity with the fetal no observed adverse effect level representing approximately 0.3 times the mrhd on a bsa basis. in a rat pre-and post-natal developmental study (dosing from implantation through weaning) conducted at subcutaneous doses of 4.4, 13.3, & 40 mg/kg, decreased pup survival was observed at the high dose. the high dose is comparable to the daily mrhd of 400 mg/day on a bsa basis. 8.2 lactation risk summary lactation studies have not been conducted with bupivacaine. bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. bupivacaine hydrochloride should be administered to lactating women only if clearly indicated. studies assessing the effects of bupivacaine hydrochloride in breastfed children have not been performed. studies to assess the effect of bupivacaine hydrochloride on milk production or excretion have not been performed. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for bupivacaine and any potential adverse effects on the breastfed child from bupivacaine or from the underlying maternal condition. 8.4 pediatric use bupivacaine hydrochloride is approved for use in adults. administration of bupivacaine hydrochloride in pediatric patients younger than 12 years is not recommended. continuous infusions of bupivacaine in pediatric patients have been reported to result in high systemic levels of bupivacaine and seizures; high plasma levels may also be associated with cardiovascular abnormalities. 8.5 geriatric use patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with bupivacaine hydrochloride. in clinical studies of bupivacaine, elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger adult patients. differences in various pharmacokinetic parameters have been observed between elderly and younger adult patients [see clinical pharmacology]. this product is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. elderly patients may require lower doses of bupivacaine hydrochloride. 8.6 hepatic impairment amide-type local anesthetics, such as bupivacaine, are metabolized by the liver. patients with severe hepatic impairment, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations, and potentially local anesthetic systemic toxicity. therefore, consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment treated with bupivacaine hydrochloride, especially with repeat doses [see warnings and precautions]. 8.7 renal impairment bupivacaine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment. this should be considered when selecting the bupivacaine hydrochloride dosage [see use in specific populations].

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride injection or diltiazem hydrochloride for injection are indicated for the following: atrial fibrillation or atrial flutter temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. it should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wolff-parkinson-white (wpw) syndrome or short pr syndrome. in addition, diltiazem hydrochloride injection is indicated for: paroxysmal supraventricular tachycardia rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm. this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndrome. unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. the use of diltiazem hydrochloride injection or diltiazem hydrochloride for injection should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. for either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ecg and frequent measurement of blood pressure. a defibrillator and emergency equipment should be readily available. in domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. heart rate reduction may last from 1 to 3 hours. if hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. a 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). hypotension, if it occurs, may be similarly persistent. in the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. in domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting psvt to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. injectable forms of diltiazem are contraindicated in: patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker. patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker. patients with severe hypotension or cardiogenic shock. patients who have demonstrated hypersensitivity to the drug. intravenous diltiazem and intravenous beta-blockers should not be administered together or in close proximity (within a few hours). patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wpw syndrome or short pr syndrome. as with other agents which slow av nodal conduction and do not prolong the refractoriness of the accessory pathway (e.g., verapamil, digoxin), in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with injectable forms of diltiazem. as such, the initial use of injectable forms of diltiazem should be, if possible, in a setting where monitoring and resuscitation capabilities, including dc cardioversion/defibrillation, are present (see overdosage). once familiarity of the patient's response is established, use in an office setting may be acceptable. patients with ventricular tachycardia. administration of other calcium channel blockers to patients with wide complex tachycardia (qrs ≥ 0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. it is important that an accurate pretreatment diagnosis distinguish wide complex qrs tachycardia of supraventricular origin from that of ventricular origin prior to administration of injectable forms of diltiazem. to use vial in add-vantage® flexible diluent container to open: peel overwrap at corner and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to assemble vial and flexible diluent container: (use aseptic technique) remove the protective covers from the top of the vial and the vial port on the diluent container as follows:to remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (see figure 1.), then pull straight up to remove the cap. (see figure 2.) note: do not access vial with syringe. to remove the vial port cover, grasp the tab on the pull ring, pull up to break the tie membrane, then pull back to remove the cover. (see figure 3.) screw the vial into the vial port until it will go no further. the vial must be screwed in tightly to assure a seal. this occurs approximately 1/2 turn (180°) after the first audible click. (see figure 4.) the clicking sound does not assure a seal; the vial must be turned as far as it will go. note: once vial is seated, do not attempt to remove. (see figure 4.) recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly. label appropriately. to reconstitute the drug: squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial. with the other hand, push the drug vial down into the container telescoping the walls of the container. grasp the inner cap of the vial through the walls of the container. (see figure 5.) pull the inner cap from the drug vial. (see figure 6.) verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix. mix container contents thoroughly and use within the specified time. preparation for administration: (use aseptic technique) confirm the activation and admixture of vial contents. check for leaks by squeezing container firmly. if leaks are found, discard unit as sterility may be impaired. close flow control clamp of administration set. remove cover from outlet port at bottom of container. insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. note: see full directions on administration set carton. lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. bend the loop outward to lock it in the upright position, then suspend container from hanger. squeeze and release drip chamber to establish proper fluid level in chamber. open flow control clamp and clear air from set. close clamp. attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. regulate rate of administration with flow control clamp. warning: do not use flexible containers in series connections. compatibility: diltiazem hydrochloride injection and diltiazem hydrochloride for injection were tested for compatibility with three commonly used intravenous fluids at a maximal concentration of 1 mg diltiazem hydrochloride per milliliter. diltiazem hydrochloride injection and diltiazem hydrochloride for injection were found to be physically compatible and chemically stable in the following parenteral solutions for at least 24 hours when stored in glass (diltiazem hydrochloride injection only) or polyvinylchloride (pvc) bags at controlled room temperature 20° to 25°c (68° to 77°f) [see usp] or under refrigeration 2° to 8°c (36° to 46°f). dextrose (5%) injection usp sodium chloride (0.9%) injection usp dextrose (5%) and sodium chloride (0.45%) injection usp physical incompatibilities: because of potential physical incompatibilities, it is recommended that diltiazem hydrochloride injection or diltiazem hydrochloride for injection not be mixed with any other drugs in the same container. if possible, it is recommended that diltiazem hydrochloride injection or diltiazem hydrochloride for injection not be co-infused in the same intravenous line. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. diltiazem hydrochloride injection. physical incompatibilities (precipitate formation or cloudiness) were observed when diltiazem hydrochloride injection was infused in the same intravenous line with the following drugs: acetazolamide, acyclovir, aminophylline, ampicillin, ampicillin sodium/sulbactam sodium, cefamandole, cefoperazone, diazepam, furosemide, hydrocortisone sodium succinate, insulin, (regular: 100 units/ml), methylprednisolone sodium succinate, mezlocillin, nafcillin, phenytoin, rifampin, and sodium bicarbonate. diltiazem hydrochloride for injection. physical incompatibilities (precipitate formation or cloudiness) were observed when diltiazem hydrochloride for injection at a concentration of 1 mg/ml diluted in normal saline was infused in the same intravenous line with the following drugs: acetazolamide, acyclovir, cefoperazone sodium, diazepam, furosemide, phenytoin and rifampin. note: diltiazem hydrochloride for injection at a concentration of 1 mg/ml diluted in normal saline was infused in the same intravenous line and was found to be compatible with the following drugs: aminophylline, ampicillin sodium, ampicillin sodium/sulbactam sodium, cefamandole, hydrocortisone sodium succinate, regular insulin (100 units/ml), methylprednisolone sodium succinate, mezlocillin sodium, nafcillin sodium and sodium bicarbonate. transition to further antiarrhythmic therapy. transition to other antiarrhythmic agents following administration of diltiazem hydrochloride injection is generally safe. however, reference should be made to the respective agent manufacturer's package insert for information relative to dosage and administration. in controlled clinical trials, therapy with antiarrhythmic agents to maintain reduced heart rate in atrial fibrillation or atrial flutter or for prophylaxis of psvt was generally started within 3 hours after bolus administration of diltiazem hydrochloride injection. these antiarrhythmic agents were intravenous or oral digoxin, class 1 antiarrhythmics (e.g., quinidine, procainamide), calcium channel blockers, and oral beta-blockers. experience in the use of antiarrhythmic agents following maintenance infusion of diltiazem hydrochloride injection is limited. patients should be dosed on an individual basis and reference should be made to the respective manufacturer's package insert for information relative to dosage and administration.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (av) heart block with syncopal seizures (stokes-adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. in cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. epinephrine should not be used in the presence of car

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - enalaprilat (unii: gv0o7es0r3) (enalaprilat anhydrous - unii:q508q118jm) - enalaprilat injection, usp is indicated for the treatment of hypertension when oral therapy is not practical. enalaprilat injection, usp has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. in using enalaprilat injection, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection, usp does not have a similar risk. (see warnings.) in considering use of enalaprilat injection, usp, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (see warnings, angioedema). enalaprilat injection, usp is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - myocardial infarction metoprolol tartrate injection is indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used in conjunction with oral metoprolol tartrate maintenance therapy. treatment with intravenous metoprolol tartrate can be initiated as soon as the patient's clinical condition allows (see dosage and administration,contraindications, and warnings). hypersensitivity to metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross sensitivity between beta-blockers can occur). myocardial infarction metoprolol tartrate is contraindicated in patients with a heart rate <45 beats/min; second-and third-degree heart block; significant first-degree heart block (p-r interval ≥0.24 sec); systolic blood pressure <100 mmhg; or moderate-to-severe cardiac failure (see warnings).

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20, sodium cation - unii:lyr4m0nh37) - sodium bicarbonate injection, usp is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. but since an appreciable time int

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37) - sodium chloride injection, usp is indicated as a source of water and electrolytes. 0.9% sodium chloride injection, usp is also indicated for use as a priming solution in hemodialysis procedures. none known.